Tabar, Ana IDelgado, JulioGonzález-Mancebo, EloinaArroabarren, EsoziaSoto Retes, LorenaDomínguez-Ortega, JavierSpanish Allergy and Clinical Immunology Scientific Society (SEAIC)2023-02-092023-02-092021-02-25http://hdl.handle.net/10668/17234The Global Initiative for Asthma Report updated in 2019 stated that potential benefits of allergen immunotherapy (AIT), compared to pharmacological and avoidance options, must be weighed against the risk of adverse effects and the inconvenience and cost of the prolonged course of therapy in asthma. Thus, with the aim of clarifying some aspects with regard to the possible use of AIT in allergic asthma treatment armamentarium, a group of expert allergists from the Spanish Allergy and Clinical Immunology Scientific Society (SEAIC), particularly from the Immunotherapy and Asthma Interest Groups developed a frequently asked questions in clinical practice. This document updates relevant topics on the use of AIT in asthma and could facilitate physician clinical decisions and improve health outcomes for individual patients.enAllergyAsthmaClinical practiceImmunotherapyAge FactorsAllergensAntibody SpecificityAsthmaBiomarkersClinical Decision-MakingClinical Trials as TopicCost-Benefit AnalysisDesensitization, ImmunologicDisease ManagementHumansImmunoglobulin EPrognosisSeverity of Illness IndexTreatment Outcomeresearch article33631755open access10.1159/0005138111423-0097https://www.karger.com/Article/Pdf/513811